Business
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results
Soquelitinib data from cohorts 1-3 of atopic dermatitis Phase 1 clinical trial demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 Phase 3 registrational clinical trial of soquelitinib in peripheral T cell lymphoma (PTCL) enrolling with multiple clinical sites open Early exercise of common stock warrants by stockholders providing cash proceeds of approximately $31.3 million Soquelitinib data to be highlighted on conference
About this update from Corvus Pharmaceuticals, Inc.
[{"type":"image","alt":"Corvus Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Corvus Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":63,"url":"https://media.zenfs.com/en/globenewswire.com/0c48ecf7a8b7010ea2641e33fdb6724a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/aOq6Ap2mYOyctX3DvsKQtA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/0c48ecf7a8b7010ea2641e33fdb6724a","width":300,"height":63}},"lazy":false},{"type":"text","content":"Soquelitinib data from cohorts 1-3 of atopic dermatitis Phase 1 clinical trial demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2","length":204,"tagName":"p"},{"type":"text","content":"Phase 3 registrational clinical trial of soquelitinib in peripheral T cell lymphoma (PTCL) enrolling with multiple clinical sites open","length":134,"tagName":"p"},{"type":"text","content":"Early exercise of common stock warrants by stockholders providing cash proceeds of approximately $31.3 million","length":110,"tagName":"p"},{"type":"text","content":"Soquelitinib data to be highlighted on conference call and webcast today at 4:30 p.m. ET / 1:30 p.m. PT","length":103,"tagName":"p"},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the first quarter ended March 31, 2025.","length":258,"tagName":"p"},{"type":"text","content":"“The new soquelitinib data being presented at the Society for Investigative Dermatology annual meeting supports its potential to be a meaningful new treatment for atopic dermatitis, along with the broader opportunity for ITK inhibition to provide a new mechanism of action to treat a range of immune diseases,” said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus. “Looking forward, we remain on track with our key potential value-driving initiatives for soquelitinib in atopic dermatitis, including data from our new extension cohort in the fourth quarter and initiating a Phase 2 clinical trial before year-end. We also remain excited about our other soquelitinib clinical programs – patient enro...